Pfizer, Inc. (PFE) Given a $38.00 Price Target at Deutsche Bank AG

Deutsche Bank AG set a $38.00 price target on Pfizer, Inc. (NYSE:PFE) in a report released on Wednesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

PFE has been the topic of a number of other research reports. Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the stock a buy rating in a report on Monday, July 17th. BMO Capital Markets upgraded Pfizer from a market perform rating to an outperform rating and upped their price target for the stock from $33.00 to $37.00 in a report on Wednesday, August 2nd. UBS AG restated a buy rating and issued a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. ValuEngine upgraded Pfizer from a hold rating to a buy rating in a report on Friday, October 6th. Finally, BidaskClub upgraded Pfizer from a strong sell rating to a sell rating in a report on Friday, June 23rd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $38.10.

Pfizer (PFE) traded down 0.058% during trading on Wednesday, hitting $36.429. The stock had a trading volume of 7,803,369 shares. The firm has a market cap of $216.66 billion, a P/E ratio of 26.649 and a beta of 1.00. The stock’s 50 day moving average price is $35.02 and its 200 day moving average price is $33.73. Pfizer has a 12-month low of $29.83 and a 12-month high of $36.60.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.64 EPS. On average, analysts anticipate that Pfizer will post $2.56 EPS for the current fiscal year.

WARNING: This piece was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/10/12/pfizer-inc-pfe-given-a-38-00-price-target-at-deutsche-bank-ag.html.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.51%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio is presently 94.12%.

In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Ian C. Read sold 197,168 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the transaction, the chief executive officer now directly owns 580,318 shares in the company, valued at approximately $19,730,812. The disclosure for this sale can be found here. In the last three months, insiders have sold 464,521 shares of company stock worth $15,813,961. Corporate insiders own 0.06% of the company’s stock.

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after purchasing an additional 9,239,499 shares during the period. Franklin Resources Inc. lifted its stake in shares of Pfizer by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after purchasing an additional 389,629 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Pfizer by 4.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after purchasing an additional 2,028,313 shares during the period. Fisher Asset Management LLC lifted its stake in shares of Pfizer by 3.9% during the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after purchasing an additional 1,275,832 shares during the period. Finally, LSV Asset Management lifted its stake in shares of Pfizer by 0.6% during the 2nd quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock worth $1,117,726,000 after purchasing an additional 199,100 shares during the period. 68.99% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply